Dyax Corp. Announces Fourth Quarter and Full Year 2013 Financial Results

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Dyax Corp. (NASDAQ: DYAX) today announced financial results for the fourth quarter and year ended December 31, 2013. Dyax will host a webcast and conference call at 8:30 a.m. (ET) today to review financial results and provide updates regarding its key value drivers – the hereditary angioedema (HAE) business, including KALBITOR® (ecallantide) and DX-2930, and the Licensing and Funded Research Portfolio (LFRP).

Help employers find you! Check out all the jobs and post your resume.

Back to news